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Around the world, patients with a variety of diseases unresponsive 
to conventional medicines are travelling to various destinations to 
receive stem cell therapies – a phenomenon known as ‘stem cell 
tourism’. This raises significant ethical concerns, as patients receive 
treatments that are unproven, often unregulated, potentially 
dangerous, and often fraudulent.1 
Stem cell research remains at the experimental stage, with clinical 
trials uncommon. However, over 700 clinics are estimated to be 
operating in mostly developing countries such as Costa Rica, 
Argentina, China, India, Russia and South Africa (SA).2 They have 
lured many patients, mostly from industrialised countries, whose 
desperation and hope are fuelling the growth of such tourism.3 
Although most countries have regulations for conducting research 
with human subjects, as well as medical malpractice and licensing 
laws, some guidelines are not specific to stem cell therapy.1 While 
international agreements may help close this regulatory gap, some 
countries don’t accept or abide by these.1 Unscrupulous individuals 
may also evade these rules.1 
Increasing use of social media has made it easier for bogus doctors 
to advertise their ‘miracle’ cures as routine therapies and entice their 
victims with the promise that stem cells hold. Many services offered 
to medical tourists are legitimate, provided by reputable hospitals 
and health professionals. However, there is no evidence for the 
efficacy of most stem cell therapies, except for cell transplants for 
some blood disorders.3
For a medical innovation to be ethically responsible, it should be 
based on animal studies or other research that guarantees evidence 
of safety and clinical efficacy. Stem cell therapies offer hope for those 
in frantic need of a remedy. Therefore, what are the implications 
if an individual is administered a therapy that is unproven in an 
unregulated environment?
We examine the South African legal framework regulating stem 
cell therapy and the effects of unproven stem cell treatments, and 
conclude with recommendations that may help to strengthen 
the legal position. We focus on legal issues relating to stem cell 
therapy and not stem cell research, where different legal and ethical 
considerations apply. 
Effect of unproven stem cell therapies
In the late 1990s, two South African researchers at the University 
of Pretoria tested an experimental drug, Virodene P058, on human 
participants, without ethical review committee approval and proper 
peer review.4 Health professionals opposed to Virodene sparred with 
prominent political figures including Thabo Mbeki, then SA’s deputy 
president, who backed the researchers’ efforts.4 The University of 
Pretoria ultimately reprimanded the two doctors for conducting the 
trial without approval, and blocked further tests as the substance 
was potentially harmful and there was scant evidence it would work.4 
This example emphasises the importance of peer review for health 
research and the importance of research ethics committees to 
safeguard human participants from unethical conduct. The National 
Department of Health’s 2004 Guidelines on Ethics in Health Research: 
Principles, Structures and Processes state that all health research must 
be approved by research ethics committees before the study begins.5
A dramatic example is that of a young boy who developed a multi-
focal brain tumour following treatment in Russia, where human fetal 
neural (brain) stem cells were administered into his spinal cord.6 
After several treatments, and four years after his first treatment, he 
developed tumours at the treatment sites.6 Here, the safety of the 
procedure was unproven and there was no experimental or pre-
clinical evidence to suggest that it might work.6
SA has had its stem cell operators. Laura Brown (now deceased) and 
Steve van Rooyen fled to SA after their fraudulent stem cell operations 
were exposed in the USA. In 2002 they defrauded individuals 
suffering from ALS, multiple sclerosis and other incurable diseases, 
obtaining money from them by false and fraudulent pretences 
and representations.7 Their company, Biomark, claimed to provide 
miracle cures for many diseases through the use and injection of 
stem cells derived from cord blood, for fees ranging from US$10 000 
to US$32 000 or at times negotiated by the customer.7 They recruited 
customers by claiming that the therapeutic power of stem cells 
was scientifically proven, and that Biomark was simply making it 
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available. However, these therapies were unproven and unlicensed. 
Furthermore, the same type and quantity of the same type of stem 
cells were injected into every patient, most of whom suffered from 
different illnesses.7 None of their patients were cured and many died 
from their illnesses during the course of their treatments.
Unproven therapies do not meet the minimal ethical, scientific or 
medical standards of safety and efficacy2 and their alleged success is 
based on unreliable evidence8,9 and patients’ self-reports.1 No scientific 
rationale supports these unproven therapies and post-treatment care 
is seldom provided, which in itself could be detrimental.10 
There is no medico-legal protection or coverage or medical 
practitioners’ insurance for stem cell therapies.10 The treatments are 
rarely reviewed by ethics committees, data are not collected, research 
is not published in peer-reviewed journals and charges are exorbitant 
for treatments that are no more than experimental.10 Many treatments 
are offered in countries where there is no legal pathway for medical 
negligence claims.10 Often there is also no ethics review process to 
ensure proper conduct by a doctor or researcher, and protect patients 
from the unscrupulous use of unproven treatments. As their results are 
not published, which would subject them to international peer review, 
these scientists are unaccountable for their actions.10 
The Health Professions Council of South Africa (HPCSA) and 
Medicines Control Council (MCC) have issued guidelines to regulate 
the good practice of healthcare professionals and researchers; 
protect patients and research subjects; and regulate the registration 
of medicines, including biological medicines.11-16 International 
guidelines also protect the rights of patients, emphasise the need 
to safeguard vulnerable populations and stress the importance of 
reviews by accredited research ethics committees.17-20 Unproven 
stem cell treatments contradict the guidelines and policies that form 
the framework of the medical profession. 
The International Society for Stem Cell Research (ISSCR) offers its 
Guidelines for the Clinical Translation of Stem Cells,21 which were 
developed by a team of stem cell researchers, clinicians, ethicists, 
and regulatory officials from 13 countries. These condemn the 
administration of unproven applications of stem cells or their direct 
derivatives to a large series of patients outside of a clinical trial, 
particularly when patients are charged for such services.21 Scientists, 
clinicians and healthcare and research institutions may not ethically 
participate in such activities. Regulators in countries where such 
illegitimate therapies are offered have a responsibility to prevent 
exploitation of patients and, if necessary, to close fraudulent clinics 
and take disciplinary action against the clinicians involved.21 The 
ISSCR offers a guide21 to help individuals make informed choices 
when contemplating a stem cell-based intervention either locally or 
abroad. It points out that:
• There is a long process of laboratory studies and clinical research 
to show that a treatment is safe and effective. Like a new drug, 
stem cell therapies must be assessed and meet certain standards 
before national regulatory bodies approve their use.
• Doctors have been transferring blood stem cells by bone 
marrow transplant for >50 years, and advanced techniques 
are used clinically to collect blood stem cells. Umbilical cord 
blood is often collected as a source of blood stem cells, 
for experimental use as an alternative to bone marrow in 
transplantation. Other tissue-specific stem cells, such as for skin 
and corneas, have played a role in tissue transplants for several 
years, contributing to long-term regeneration. Other stem cell 
treatments are still experimental. 
• Unlike drugs, stem cells cannot necessarily be produced and tested 
for quality in large batches, and treatments may even be patient 
specific. For most diseases, it is still being determined which cells 
will best repair a particular damaged or diseased tissue, and how 
to get them to the right place in the body. Side-effects and long-
term safety must also be determined, since transplanted cells 
may remain in patients’ bodies for many years. Therefore, careful 
monitoring and extended follow-up of patients who receive stem 
cell treatments is extremely important.
• To test whether and how a new intervention may work for a 
particular disease or injury, studies are done first in vitro and, if 
possible, in animals with a disease or injury similar to those in 
humans. These preclinical studies should be reviewed by other 
experts, published and repeated before the research is extended 
to human subjects. After demonstrating a reasonable expectation 
that the treatment will work and be safe, permission is sought to 
conduct a clinical trial in humans, starting with a few individuals. 
New experimental treatments may sometimes be carried out on 
a very small number of people before a clinical trial is started. As 
the safety and side-effects are better understood and methods for 
delivery of the treatment to the correct part of the body improve, 
the number of patients may be gradually increased and the new 
intervention compared with existing treatments. Once safety and 
effectiveness is demonstrated, the relevant regional regulatory 
agency should approve the use of the treatment for particular 
diseases or conditions.
• No medical treatment can be described as completely safe as all 
may involve risk, albeit small. Even small risks should be explained 
clearly by a medical professional.
• Patients must be sure that there is good scientific evidence that the 
treatment is safe and effective, and that their rights are respected.
• Patients should be cautious if claims are based on anecdotal 
evidence; if multiple diseases are treated with the same cells; the 
source of the cells or how the treatment will be done is not clearly 
documented; practitioners claim there are no risks; or in cases of 
high or hidden treatment costs. 
Registration of medicines in SA
The registration of medicines in SA is governed by the provisions 
and requirements of the Medicines and Related Substances Control 
Act22 (MRSCA). The Guidelines for the Registration of Medicines23 
aim to help applicants prepare documentation for the registration 
of medicines for human use.23 These guidelines are relevant only 
to human medicines, including biological and complementary 
medicines. Legislation requires that the MCC shall register every 
medicine before it may be sold or marketed,22 and an application for 
registration must be submitted for approval. 
In terms of the National Health Act, it is often unclear whether stem 
cell therapy should be regarded as a ‘health service’, which includes 
medical treatment, ‘therapeutic’ or ‘non-therapeutic research’, or 
‘health services for experimental or research purposes’.24 Each has 
different legal and ethical considerations, depending on whether 
cell-based therapy is viewed as medical treatment, experimental 
research or medicine.25
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Stem cell therapy – medicine?
The MCC prohibits the sale of medicine that is subject to registration 
but not registered.22 An exception would be where inter alia medical 
practitioners compound such medicine for a particular patient in the 
course of practising their profession, in a quantity not greater than that 
required for treatment, as determined by such medical practitioner.
The MRSCA defines a medicine as any substance or mixture of 
substances used, or purporting to be suitable for use, or manufactured 
or sold for use in:
• the diagnosis, treatment, mitigation, modification or prevention 
of disease, abnormal physical or mental states or the symptoms 
thereof in humans 
• restoring, correcting or modifying any somatic or psychic or 
organic function in humans.
The MRSCA also applies to any veterinary medicine.22 
Biological medicines are a highly specialised class of medicine, 
produced using living organisms. They are complex protein 
structures typically much larger than traditional chemical medicines, 
and are mostly administered by injection. Biological medicines 
are more advanced than conventional therapies.26 However, even 
though clinically effective, they are very expensive in SA.26
The MRSCA does not define a biological medicine. The Guidelines,23 
however, categorise biological medicine as a type of medicine23 
and define it as a medicine where the active ingredient and/or key 
excipients have been derived from living organisms or tissues, or 
manufactured using a biological process. Biological medicines can 
be defined largely by reference to their method of manufacture (the 
biological process). These include inter alia medicines prepared from 
the following substrates: (i) microbial cultures (fermentation); (ii) plant 
or animal cell cultures (including those resulting from recombinant 
DNA or hybridoma techniques); (iii) extraction from biological tissues; 
and (iv) propagation of live agents in embryos or animals.
Biological medicines include, but may not be limited to: (i) plasma-
derived products, e.g. clotting factors, immunosera, etc; (ii) vaccines; 
(iii) biotechnology-derived medicinal products (rDNA products), 
e.g. rHu-antihaemophilic factors, hormones, cytokines, enzymes, 
monoclonal antibodies, erythropoietins; and (iv) human gene therapy. 
In SA, it has been the practice that the MCC can decide to exclude 
certain well-characterised, low-molecular weight medicinal 
biological compounds from biological medicine status, such as 
antibiotics, insulin, etc. These compounds are therefore not reviewed 
by the Biological Medicines Committee.22 
By these definitions, a stem cell product (or application) falls within 
the ambit of a biological medicine. The position of autologous 
stem cell therapy (ASC), however, is less clear. ASC involves 
the removal of the patient’s own stem cells, which are cultured 
and often mixed with other therapeutic substances, stored or 
cryopreserved, then administered back to the patient, typically 
by injection. The question of whether ASC may be viewed as a 
biological medicine or not hinges on the nature of the ‘product’ 
thus created, and whether it is essentially still part of the person’s 
body or something entirely new.
The autologous stem cell therapy Regenexx attracted worldwide 
attention when the USA regulatory authority, the Food and Drug 
Administration (FDA), filed suit against its developers, Regenerative 
Sciences. The FDA claimed that the stem cell-based product 
developed during the Regenexx procedure is a ‘biological product’ 
that, in addition to claims regarding its therapeutic use, makes 
it subject to FDA regulation.27 The FDA calls the procedure the 
‘manufacturing, holding for sale, and distribution of an unapproved 
biological drug product’, and in 2010, ordered Regenerative Sciences 
to stop offering the treatment. 
The court noted that ‘the biological characteristics of the cells 
change during the process’, and that this, together with other 
factors, means the cells are more than ‘minimally manipulated’. 
While the court held that ‘maintaining the FDA’s role as watchdog 
and regulatory authority is imperative,’27 Regenerative Sciences 
asserted that the FDA’s mandate is to regulate mass production of 
drugs by pharmaceutical companies and not ‘one-on-one’ doctor-
patient risks. 
If the MRSCA and the Guidelines for the Registration of Medicines 
are interpreted strictly, stem cell products similar to Regenexx 
must be registered as a biological medicine in SA. For this to 
happen, the MCC should be convinced of their efficacy, safety and 
quality.22,23 The harvesting of stem cells, as well as their isolation, 
cryopreservation and any other activity affecting them, must also 
comply with the relevant requirements stipulated in Chapter 8 of 
the National Health Act and the 2012 Regulations Relating to the 
Use of Human Biological Material.28 
In contrast to the NHA, which requires ministerial authorisation for 
the removal of stem cells from living persons, these regulations refer 
only to the informed consent of the patient whose cells are removed. 
This oversight creates practical obstacles for routine procedures, 
particularly bone marrow transplantation.29 
Regulation 2(1) of the 2012 Regulations Relating to Stem Cell 
Banks30 also states that no person may release stem cell products for 
therapeutic use unless this is authorised in terms of section 54 of the 
National Health Act and, where relevant, laboratory tests for certain 
transmissible diseases have been performed. However, Regulation 
2(1)(2) stipulates that this may not be required where the stem cells 
are for autologous use. In addition, Regulation 2(1)(3) states that no 
person may use stem cell products for therapeutic use unless they are 
registered with the Health Department and, among other things, 
relevant written (and duly documented voluntary) consent has been 
obtained from the donor of the cells, even in the case of residual 
tissue, blood or blood products.
Registration of a biological medicine with 
the MCC
Since the MRSCA requires that the MCC shall register every 
medicine before it may be sold and marketed, an application 
for such registration should be submitted for evaluation and 
approval.22,23Applications to register medicine for humans are 
divided into different types to determine fees and allocate reviewers 
for evaluation.23 One of these types is biological medicine. It is legally 
required that data submitted for evaluation should substantiate all 
claims and meet the technical requirements. 
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The MCC refers to international guidelines to be read in conjunction 
with the South African guidelines, in particular the International 
Conference on Harmonisation of Technical Requirements for 
Registration of Pharmaceuticals for Human Use (ICH). The ICH aims 
to achieve greater harmonisation to ensure that safe, effective and 
high-quality medicines are developed and registered in the most 
resource-efficient manner.31 It promotes public health, prevents 
unnecessary duplication of clinical trials in humans, and minimises 
the use of animal testing without compromising safety and 
effectiveness.31 Therefore, applications to register a medicine must 
ensure that the product meets the technical requirements of quality, 
safety and efficacy for its intended use.
After the administrative steps for registration have been submitted,23 
biological medicines require primary evaluation by the Biological 
Medicines Committee, in addition to other committees of the MCC. 
The MCC may choose to accept, defer or reject the application. 
Should the application be deferred, the applicant will be required to 
produce additional information and re-submit the application. Once 
the application is accepted, the biological medicine is registered with 
the MCC and may be sold and marketed.
Failure to register a stem cell therapy as prescribed contravenes section 
14(1) of the MRSCA and is an offence in terms of section 29, punishable 
by a fine or imprisonment of a period not exceeding 10 years.
Conclusion
The increasing demand for stem cell therapies should be countered 
by efforts to raise public awareness about the types of treatments 
that are scientifically sound and safe. To date, proven stem cell 
treatments include bone marrow transplants, bone and skin grafts, 
and treatments for blood and immune disorders, leukaemia and 
corneal disease. Patients must be informed that multiple diseases 
cannot be treated with the same type of stem cells. 
Weak legal enforcement of the MRSCA permits the emergence 
of medically unsound and unethical practices that may exploit 
emotionally vulnerable patients.6 The only trusted sources of 
evidence confirming that a treatment is safe and effective are 
(i) independent clinical trials, approved by government regulatory 
agencies; (ii) evidence of ethical clearance; (iii) publication and 
peer review assessment in international scientific journals; and 
(iv) replication of results by other laboratories.
False advertisement and promises of miracle cures should be banned. 
Stringent rules are needed to ensure that pre-clinical studies and well-
controlled clinical trials have been conducted before introducing cells 
into the patient.6 There must be well-proven records which indicate 
that the desired therapeutic effect will, under normal circumstances, 
be achieved.6 The person who administers such therapies must 
be medically qualified and familiar with stem cell therapies for a 
prescribed number of years. Furthermore, any work involving stem 
cells that will be (re)introduced into patients must be conducted in 
accredited or authorised institutions only, under strictly controlled 
conditions6 to ensure that this material is not contaminated and that 
no adverse effects will be produced under normal conditions. 
Despite the legal requirements for the registration of biological 
medicines, the MCC has capacity problems and an ineffective law 
enforcement arm.32 The most recent example is the inability of the 
MCC’s law enforcement unit to deal with the so-called ‘snake doctors’ 
who offer bogus medical cures, including for HIV and AIDS. To 
compound the existing situation, the legal framework relating to the 
regulation of human tissues is generally unsatisfactory.33
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